EASI

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Atopic dermatitis, Itch, Psoriasis, BSA, Clinical research, Dermatitis, Body surface area, Roivant Sciences, Patient, Rady, Physician, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Common, Atopic dermatitis, Itch, Psoriasis, Stinger, Swelling, BSA, Irritation, Clinical research, Dermatitis, Body surface area, Nose, Patient, Roivant Sciences, Rady, Physician, Pain, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Rash, Folliculitis, Incidence, Headache, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

Retrieved on: 
Monday, March 13, 2023
Abstract, NORTH, AAD, Research, Psoriasis, NYSE, ABBV, Atopic dermatitis, Itch, Head, AbbVie, Quality of life, American Academy, Dermatology, Patient, Hidradenitis suppurativa, Safety, Sleep, EASI, Risankizumab, Pharmaceutical industry

NORTH CHICAGO, Ill., March 13, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21, in New Orleans, Louisiana.  

Key Points: 
  • "The data at this year's AAD conference demonstrate AbbVie's commitment to investing in its dermatology portfolio to further improve outcomes for patients with immune-mediated skin conditions," said Celine Goldberger, M.D., vice president, head of U.S. medical affairs, AbbVie.
  • The oral and poster presentations from AbbVie highlight research across the company's collective portfolio, further demonstrating leadership in dermatology innovation.
  • Data feature outcomes in psoriatic disease, atopic dermatitis and hidradenitis suppurativa to support patients living with immune-mediated skin conditions.
  • The 2023 AAD Annual Meeting e-Posters are available here and late-breaking sessions are available here .

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

Retrieved on: 
Friday, February 24, 2023
Safety, CMO, Patient, SAN, ASLN, AD, Physician, Pharmaceutical industry, EASI

ASLAN expects to report topline data from this study in early July 2023.

Key Points: 
  • ASLAN expects to report topline data from this study in early July 2023.
  • The randomized, double-blind, placebo-controlled, dose-ranging clinical study, TREK-AD, was initiated in early 2022 to evaluate the efficacy and safety of eblasakimab in biologic naïve AD patients during a 16-week treatment period and a 12-week safety follow-up period.
  • The study has enrolled patients from more than 80 sites across North America, Europe and Asia Pacific.
  • “We are grateful to all patients, physicians, and trial investigators involved in the study.

Evelo Biosciences Provides Clinical and Business Updates

Retrieved on: 
Wednesday, February 1, 2023
Prevalence, Geography, Food, Psoriasis Area and Severity Index, Patient, Science, EV, Trial of the century, Webcast, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Atopic dermatitis, EASI, Partnership, Clinical trial, Health care, FDA, Psoriasis, Phase 3, EMA, Workforce, Medication, MHRA, Medical imaging, Vaccine, Management, Silviculture, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.

Key Points: 
  • ET –
    CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.
  • Based on their feedback, we believe we have a clear path towards a global registration program for EDP1815 in psoriasis.
  • As part of this initiative, we have reduced our workforce and are prioritizing investment in our core clinical programs.
  • Evelo is in active discussions regarding partnership opportunities across EDP1815, EDP2939, as well as the EV platform.

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, October 28, 2022
Â, Clinical trial, ESDR, American depositary receipt, AD, Development, European Society for Medical Oncology, Feinberg School of Medicine, Itch, Safety, Nasdaq, B cell, CEO, European Academy of Microbiology, ADS, Patient, Research, Technology, EASI, News, GLOBE, Trial, Johns Hopkins University, SAN, Eosinophil, Investment, New York Public Library, ASLN, Congress, Sleep, Investor relations, Biomarker, Pharmaceutical industry, Cryptocurrency, Company, Dupilumab, Venereology, Dermatology

Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.

Key Points: 
  • Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.
  • Research and development expenses were US$8.0 million in the third quarter of 2022 compared to US$5.3 million in the third quarter of 2021.
  • General and administrative expenses were US$2.3 million in the third quarter of 2022 compared to US$2.8 million in the third quarter of 2021.
  • Net loss attributable to stockholders for the third quarter of 2022 was US$10.9 million compared to a net loss of US$8.6 million for the third quarter of 2021.

LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Atopic dermatitis, Disease, Royal commission, Population, Review, Science, GPER, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Poster, Sleep, IGA, EASI, Research, MPH, University, Food, Adolescence, Department, Ludwig Maximilian University of Munich, Â, Leo Pharma, United Arab Emirates, Adult, Ageing, Safety, LEO, Dermatitis, DKK, EC, AD, European, European Commission, Week, Itch, FDA, Pharmaceutical industry, Vaccine, Tralokinumab, Dermatology

The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein.

Key Points: 
  • The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein.
  • The European Commissions approval of Adtralza for use in adolescent patients is a demonstration of our relentless commitment to bringing new treatment options to those living with atopic dermatitis, said Christophe Bourdon, Chief Executive Officer, LEO Pharma A/S.
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis

Retrieved on: 
Wednesday, September 28, 2022
People, Janus, Adult, American Academy, EASI, Inflammation, Ocular rosacea, Safety, Awareness, Immunology, National Institute of Infectious Diseases, AD, Atopic dermatitis, Itchy, Conjunctivitis, Infection, Patient, Clinical trial, Immune-mediated inflammatory diseases, Forearm, Bleeding, Emotional well-being, Quality of life, American Academy of Dermatology, Eczema Area and Severity Index, JAK, Anxiety, Sleep, Briony Behets, Association, Overalls, PALO, BID, Skin, Asthma, HIV disease progression rates, Immune system, Depression, National Institute, Pharmaceutical industry, Vaccine, Silk, IRAK4, Dermatitis, Dermatology

The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.

Key Points: 
  • The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.
  • The Phase 2a study follows the successful completion of a Phase 1 healthy volunteer study which evaluated 18 adult patients with EVO101 0.1% topical cream, applied twice daily to the ventral aspect of one forearm for seven days.
  • In the Phase 2a study, AD patients will apply EVO101 cream twice daily for eight weeks.
  • "From inception, we have remained focused on rapidly progressing multiple candidates into proof-of-concept clinical studies," said Luis Pea, President and Chief Executive Officer of Evommune.

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Monday, September 19, 2022
Managed Care, General Health, Pharmaceutical, Health, Adult, EASI, Safety, SCORAD, FDA, AD, Food, Leo Pharma, European Medicines Agency, Week, European Commission, Population, Adolescence, Atopic dermatitis, IGA, Patient, Committee for Medicinal Products for Human Use, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Itch, Dermatology, Eczema Area and Severity Index, European Directive on Traditional Herbal Medicinal Products, United Arab Emirates, Science, CHMP, EC, Poster, Research, Ageing, DKK, NRS, Royal commission, Committee, Union, LEO, EMA, Disease, Dermatitis, Vaccine, Pharmaceutical industry, Tralokinumab, EU

There are limited treatment options for adolescents in the EU living with moderate-to-severe atopic dermatitis.

Key Points: 
  • There are limited treatment options for adolescents in the EU living with moderate-to-severe atopic dermatitis.
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.
  • Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no.